Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 2,806 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: cyclophosphamide Clear all

Conditions: Myeloma Before MV-NIS Treatment, Endometrial Cancer Before VSV-hINF-NIS Treatment
Interventions: 18F-TFB-PET; Combination Product
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Leukemia
Interventions: cyclophosphamide, filgrastim, recombinant interferon alfa, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lung Cancer
Interventions: Amrubicin, Cyclophosphamide; Drug
Lead sponsor: Lawrence Einhorn; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Springdale, Arkansas • Newark, Delaware • Galesburg, Illinois + 7 more

Conditions: Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer
Interventions: Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine, Aldesleukin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myasthenia Gravis
Interventions: Hematopoietic Stem Cell Transplantation, Cyclophosphamide, ATG (rabbit), Mesna, Methylprednisolone, G-CSF; Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 15 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lymphoma
Interventions: filgrastim, busulfan, cyclophosphamide, etoposide, melphalan, autologous-autologous tandem hematopoietic stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Sclerosis
Interventions: P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: La Jolla, California • St Louis, Missouri • New Brunswick, New Jersey + 1 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Previously Treated Myelodysplastic Syndrome, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Natural Killer Cell Therapy, Tacrolimus, Total-Body Irradiation; Procedure · Drug · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 3
States / cities: Seattle, Washington • Milwaukee, Wisconsin

Conditions: Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
Interventions: Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin; Drug
Lead sponsor: Columbia University; Other
Eligibility: Up to 30 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone, Rituximab, Vincristine Sulfate, Zanubrutinib; Drug · Biological
Lead sponsor: Yazeed Sawalha; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Cleveland, Ohio • Columbus, Ohio • Charleston, South Carolina

Conditions: Pediatric, Hodgkin's Disease
Interventions: COPP/ABV, intensive chemo with concurrent growth factor; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma (Skin)
Interventions: Tumor Infiltrating Lymphocytes (TIL); Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Untreated Follicular Lymphoma
Interventions: Surovatamig, R-CHOP, R-CVP, BR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 62
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more

Conditions: Anti-p53 TCR-Gene
Interventions: anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mantle Cell Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Ibrutinib, Methotrexate, Rituximab, Venetoclax, Vincristine Sulfate; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Refractory and/or Relapsed Metastatic Solid Tumors
Interventions: Cyclophosphamide, Fludarabine, low dose total body irradiation, Melphalan, Tacrolimus; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 1 Year to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • The Bronx, New York • Valhalla, New York

Conditions: Lymphoproliferative Disorder
Interventions: rituximab, cyclophosphamide, methylprednisolone, prednisone; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions: Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa; Drug · Radiation
Lead sponsor: Columbia University; Other
Eligibility: Up to 30 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia
Interventions: Lumiliximab with FCR; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • San Diego, California • Baltimore, Maryland + 2 more

Conditions: Systemic Lupus Erythematosus
Interventions: NKX019, Cyclophosphamide LD; Biological · Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2040
U.S. locations: 2
States / cities: New York, New York

Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Interventions: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab, Fludarabine; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hematopoietic Malignancies
Interventions: Cyclophosphamide; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia
Interventions: cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate, radiation therapy; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 3,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 116
States / cities: Phoenix, Arizona • Downey, California • Duarte, California + 92 more

Conditions: Leukemia, Lymphoma
Interventions: Capivasertib, Venetoclax, Rituximab, Blinatumomab, Nelarabine, mini-hyperCVD; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies

Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia

Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL